Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

O’Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T. H., Hochhaus, A., Hughes, T. P., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,550 · see citing works

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · see citing works

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D. J., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,785 · see citing works

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., PAQUETTE, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,608 · see citing works

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan‐Jacob, S. W., Ray, A., Huntly, B. J. P., Fabbro, D., Fendrich, G., Hall–Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,494 · see citing works

Discovery of N -(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D. J., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,303 · see citing works

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

Deininger, M. W., Buchdunger, E., & Druker, B. J. (2004) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,252 · see citing works

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,197 · see citing works

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,139 · see citing works

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036 · see citing works

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,011 · see citing works

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K. M., Herrmann, R., Lynch, K., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649 · see citing works

Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL

Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 617 · see citing works

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment

Roche‐Lestienne, C., Soenen, V., Grardel, N., Laï, J., Philippe, N., Facon, T. T. F., Fenaux, P., & Preudhomme, C. (2002) · Blood · doi:10.1182/blood.v100.3.1014 · Cited by 515 · see citing works

Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients

Peng, B., Hayes, M., Resta, D. J., Racine-Poon, A., Druker, B. J., Talpaz, M., Sawyers, C. L., Rosamilia, M., Ford, J., Lloyd, P. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.050 · Cited by 471 · see citing works

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

von Bubnoff, N. C. C., Schneller, F., Peschel, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 466 · see citing works

SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.

Golas, J. M., Arndt, K. T., Etienne, C., Lucas, J., Nardin, D., Gibbons, J. J., Frost, P., Ye, F., Boschelli, D. H., & Boschelli, F. (2003) · PubMed · Cited by 412 · see citing works

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

Corbin, A. S., Rosée, P. G. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 310 · see citing works

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 306 · see citing works

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

Willis, S. G., Lange, T., Demehri, S., Otto, S., Crossman, L. C., Niederwieser, D. W., Stoffregen, E. P., McWeeney, S. K., Kovacs, I., Park, B. S., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1036 · Cited by 298 · see citing works

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Kimura, S. H., Naito, H., Segawa, H., Kuroda, J., Yuasa, T., Sato, K., Yokota, A., Kamitsuji, Y., Kawata, E., Ashihara, E., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2209 · Cited by 238 · see citing works

Prediction of Resistance to Small Molecule FLT3 Inhibitors

Cools, J., Mentens, N., Furet, P., Fabbro, D., Clark, J., Griffin, J. D., Marynen, P., & Gilliland, D. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2148 · Cited by 180 · see citing works

Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment

Cowan‐Jacob, S. W., Guez, V., Fendrich, G., Griffin, J. D., Fabbro, D., Furet, P., Liebetanz, J., Mestan, J., & Manley, P. W. (2004) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557043487321 · Cited by 164 · see citing works

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

von Bubnoff, N. C. C., Manley, P. W., Mestan, J., Sänger, J., Peschel, C., & Duyster, J. (2006) · Blood · doi:10.1182/blood-2005-12-010132 · Cited by 159 · see citing works

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib

Al‐Ali, H. K., Heinrich, M. C., Lange, T., Krahl, R., Mueller, M., Müller, C., Niederwieser, D. W., Druker, B. J., & Deininger, M. W. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200319 · Cited by 110 · see citing works

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

von Bubnoff, N. C. C. (2005) · Blood · doi:10.1182/blood-2004-06-2445 · Cited by 89 · see citing works

Resistance to Imatinib: Mechanisms and Management

Deininger, M. W. (2005) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2005.0045 · Cited by 57 · see citing works

SRCircumventing imatinib resistance

Deininger, M. W., & Druker, B. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.006 · Cited by 30 · see citing works

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study.

Ottmann, O. G., Martinelli, G., Dombret, H., et al. (2005) · Blood · doi:10.1182/blood.v106.11.42.42 · Cited by 27 · see citing works

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML)

Kantarjian, H. M., Ottmann, O. G., Cortes, J. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3014 · Cited by 27 · see citing works

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

Talpaz, M., Rousselot, P. H., Kim, D. W., et al. (2005) · Blood · doi:10.1182/blood.v106.11.40.40 · Cited by 24 · see citing works

Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

Sawyers, C. L., Kantarjian, H. M., Shah, N. P., et al. (2005) · Blood · doi:10.1182/blood.v106.11.38.38 · Cited by 22 · see citing works

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).

Kantarjian, H. M., Ottman, O. G., Cortes, J. E., et al. (2005) · Blood · doi:10.1182/blood.v106.11.37.37 · Cited by 20 · see citing works

Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy.

Shah, N. P., Nicoll, J. M., Branford, S., et al. (2005) · Blood · doi:10.1182/blood.v106.11.1093.1093 · Cited by 15 · see citing works

Analysis of spontaneous, gamma ray- and ethylnitrosourea-induced hprt mutants in HL-60 cells with multiplex PCR

Liu, S. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i3.578 · Cited by 8 · see citing works

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013 · see citing works

Circumventing cancer drug resistance in the era of personalized medicine

Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503 · see citing works

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Ercan, D., Choi, H. G., Yun, C.-H., Capelletti, M., Xie, T., Eck, M. J., Gray, N. S., & Jänne, P. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2789 · Cited by 368 · see citing works

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer

Yoda, S., Lin, J. J., Lawrence, M. S., Burke, B. J., Friboulet, L., Langenbucher, A., Dardaei, L., Prutisto-Chang, K., Dagogo-Jack, I., Timofeevski, S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1256 · Cited by 322 · see citing works

Ba/F3 cells and their use in kinase drug discovery

Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a25f · Cited by 240 · see citing works

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Pemovska, T., Johnson, E., Kontro, M., Repasky, G. A., Chen, J., Wells, P., Cronin, C. N., McTigue, M., Kallioniemi, O., Porkka, K., et al. (2015) · Nature · doi:10.1038/nature14119 · Cited by 234 · see citing works

Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

DeRemer, D. L., Ustun, C., & Natarajan, K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.014 · Cited by 172 · see citing works

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options

Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.018 · Cited by 105 · see citing works

Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

Doggrell, S. A., & Christensen, A.-M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.534780 · Cited by 13 · see citing works

Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib

Olshen, A. B., Tang, M., Cortes, J. E., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.085977 · Cited by 20 · see citing works

Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy

Kantarjian, H. M., Baccarani, M., Jabbour, E. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2922 · Cited by 54 · see citing works

Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia

Allen‐Bard, S. (2009) · Clinical journal of oncology nursing · doi:10.1188/09.cjon.537-542 · Cited by 2 · see citing works

NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib

Goulden, S., Sutcliffe, F., & Stevens, A. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70008-6 · Cited by 5 · see citing works